AZ's Bydureon tops doc-payments list with $22B

When it comes to which brands spent the most on doctor payments, 2014 crowned a new king--and that's diabetes drug Bydureon. Maker AstraZeneca ($AZN) shelled out $22 million, helping the med eclipse Novo Nordisk's ($NVO) Victoza, one of last year's top spenders--and a head-to-head competitor. More from FiercePharmaMarketing

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.